Peter Marks, the former top FDA vaccine official who recently resigned, has joined Eli Lilly as the senior vice president of molecule discovery and head of infectious disease research. This move comes after Marks’ abrupt departure from the FDA earlier this year, following a dispute with Health and Human Services Secretary Robert F. Kennedy, Jr.
Lilly, known for its obesity and diabetes medicines, sees Marks’ expertise as a valuable addition to their team. His role will involve evaluating breakthrough science to benefit patients in both existing and emerging areas of research. Marks’ departure from the FDA marked the end of his nearly decade-long tenure as the head of the Center for Biologics Evaluation and Research, where he oversaw the review of vaccines, blood products, and genetic medicines.
During his time at CBER, Marks played a key role in the development of Operation Warp Speed, which led to the approval of COVID-19 vaccines. He also oversaw the approval of numerous cell and gene therapies for cancer and rare diseases, pushing the FDA to become more flexible in their review process. Marks’ resignation was a part of a larger wave of departures among top FDA leaders, with his replacement, Vinay Prasad, also facing controversy during his brief tenure.
Despite the risks associated with hiring a former regulator who criticized top Trump administration officials, Lilly sees the significant value in Marks’ experience and background. Many pharmaceutical companies, including Lilly, are looking to boost U.S. drug production to meet demands and avoid tariffs. The administration’s push for deals to equalize drug prices in the U.S. with those in other developed nations adds another layer of complexity to the pharmaceutical industry.
Overall, Marks’ appointment at Lilly signifies a new chapter in his career, bringing his expertise in vaccine and infectious disease research to a new setting. His contributions are expected to drive innovation and advancements in drug discovery and development within the company.
